Hoover's - A D&B Company - We Make It Easier
Buy Reports For This Company

Galena BioPharma, Inc.
Lake OswegoOR United States
  (NASDAQ: GALE)

btn-overview-2btn-people-1btn-competition-1

Company Description

While there's no vaccine for breast cancer, Galena Biopharma has big plans for NeuVax, its drug candidate. NeuVax, which is in Phase III clinical trials, is being tested for its efficacy in reducing the recurrence of breast cancer in patients who can't take Genentech's Herceptin. Galena Biopharma acquired the rights to NeuVax when it bought the drug's developer, Arizona-based Apthera, Inc., for about $7 million in April 2011. Galena itself was spun off from RXi Pharmaceuticals in a one-for-one stock split in March 2012. Galena, having more potential for success with NeuVax, became the public company while RXi Pharmaceuticals became a private company focused on developing RNA interference (RNAi) therapies.

310 N. State St.,
Ste. 208
Phone: 855-855-4253http://www.galenabiopharma.com
Lake OswegoOR 97034Map Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

btn-free-trial

Prepare for your Sales call

Try a Small Business Subscription
Starting $89 per month

btn-subscribe-now

Galena BioPharma, Inc. Rankings

Russell 2000 (June 2013)

Executives

8 executives listed for Galena BioPharma, Inc.'s Lake Oswego, OR location.
ChairmanSanford HillsbergE-mail
President, CEO, and DirectorMark AhnE-mail
EVP and COOMark SchwartzE-mail

More Galena BioPharma, Inc. Executives

Financials

Company TypePublic - NASDAQ: GALE Single Location
Fiscal Year-EndDecember
Employees6
D&B logoDNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Galena BioPharma, Inc. now.

  • Reduce risk.
  • Drive greater profitability.
  • Increase cash flow.
Get a Credit Report Now

Sponsored Links